Skip to content

Telomere Length in Relation to Acute Stress Response in Critical Care Patients

Telomere Length in Relation to Acute Stress Response in Critical Care Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03982589
Enrollment
40
Registered
2019-06-11
Start date
2017-10-01
Completion date
2018-09-30
Last updated
2019-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Disease, Telomere Shortening

Brief summary

the investigators studied the impact of severe stress (in this case any event or illness leading to a necessity of critical care) on telomere length.

Detailed description

Telomeres length analysis were determined from 2 blood samples, the initial sample drawn in the first 72 hours after hospitalization and the second after not \< 5 or \> 14 days. For patients discharged before day 5, a repeat sample was drawn and analyzed on the discharge day. The blood sample processing was as follows: 5 ml of blood was collected and the red blood cells (RBC) were lysed using the RBC lysis solution (Biological Industries, Beit Haemek, Israel). Isolation of genomic DNA was performed by using the DNA isolation kit for mammalian blood (Roche, Mannheim, Germany). Briefly, DNA was isolated by the salting out procedure, washed and precipitated by isopropanol. The DNA was resuspended in polymerase chain reaction (PCR) grade water. The DNA concentration was measured by using the NanoDrop device (Thermo Fisher, USA). DNA samples were analyzed for telomere length according to the method of Cawthon (2009) \[20\] with slight modifications. Each DNA sample was analyzed by two sets of primers detailed below, one for telomere length analysis and one for a reference gene analysis (human hemoglobin). The primers were diluted to 100µM in PCR grade water and then to 10µM. DNA samples were diluted to 2.5 ng/µl in PCR grade water. The primers sequences are shown below: telc: TGTTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAACA telg: ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT hbgd:\_GCCCGGCCCGCCGCGCCCGTCCCGCCGGAGGAGAAGTCTGCCGTT hbgu: GGCGGCGGGCGGCGCGGGCTGGGCGGCTTCATCCACGTTCACCTTG Reaction PCR were processed as follows: 50°C for 2 min, 95°C for 5 min, a single cycle of 94°C for 15 sec, 49°C for 15 sec; 40 cycles of: 94°C for 15sec, 62°C for 10 sec and a final stage of: 74°C for 15 sec. All reactions were performed using the Step One device (ABI, USA).

Interventions

None listed

Sponsors

Rabin Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* • Patients hospitalized up to 72 hours prior to admission to the ICU * Predicted ICU stay is at least 5 days

Exclusion criteria

* • Pregnancy and lactation

Design outcomes

Primary

MeasureTime frameDescription
telomere length difference7 daysthe difference between telomere length in percent between samples taken

Secondary

MeasureTime frameDescription
correlation between mortality and telomere length6 monthcorrelation between mortality and telomere length
correlation between telomere length change and leukocytes count change7 dayscorrelation between telomere length change and leukocytes count change

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026